APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Medications for Multiple Sclerosis

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oral Medications for Multiple Sclerosis Industry Research Report 2026

Report ID 174019970527 December 2025144 pages

Choose your research edition.

Industry ResearchOral Medications for Multiple Sclerosis Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Medications for Multiple Sclerosis Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oral Medications for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Medications for Multiple Sclerosis Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Medications for Multiple Sclerosis Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Oral Medications for Multiple Sclerosis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oral Medications for Multiple Sclerosis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oral Medications for Multiple Sclerosis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oral Medications for Multiple Sclerosis include Sichuan Omnis Pharmaceutical, CGeneTech (Suzhou, China), Qilu Pharmaceutical, Nanjing Healthnice Pharmaceutical, HEC Pharm, Cisen Pharmaceutical, Zydus, Viatris and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oral Medications for Multiple Sclerosis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oral Medications for Multiple Sclerosis Market by Company

Sichuan Omnis Pharmaceutical

CGeneTech (Suzhou, China)

Qilu Pharmaceutical

Nanjing Healthnice Pharmaceutical

HEC Pharm

Cisen Pharmaceutical

Zydus

Viatris

Teva

Sun Pharmaceuticals

Sanofi

Sandoz

Novartis

Mylan

Merck

Janssen

Glenmark Pharmaceuticals

Dr. Reddy's Laboratories

Bristol Myers Squibb

Biogen

Banner Life Sciences

Apotex

Alembic

Accord Healthcare

Oral Medications for Multiple Sclerosis Segment by Type

Ozanimod

Ponesimod

Fingolimod

Diroximel Fumarate

Monomethyl Fumarate

Dimethyl Fumarate

Cladribine

Teriflunomide

Siponimod

Oral Medications for Multiple Sclerosis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Oral Medications for Multiple Sclerosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Medications for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Medications for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Medications for Multiple Sclerosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oral Medications for Multiple Sclerosis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oral Medications for Multiple Sclerosis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oral Medications for Multiple Sclerosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral Medications for Multiple Sclerosis Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oral Medications for Multiple Sclerosis Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oral Medications for Multiple Sclerosis Revenue of Manufacturers (2021-2026) Table 9. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oral Medications for Multiple Sclerosis Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Oral Medications for Multiple Sclerosis Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oral Medications for Multiple Sclerosis, Product Type & Application Table 14. Global Oral Medications for Multiple Sclerosis Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oral Medications for Multiple Sclerosis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sichuan Omnis Pharmaceutical Company Information Table 19. Sichuan Omnis Pharmaceutical Business Overview Table 20. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 22. Sichuan Omnis Pharmaceutical Recent Developments Table 23. CGeneTech (Suzhou, China) Company Information Table 24. CGeneTech (Suzhou, China) Business Overview Table 25. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio Table 27. CGeneTech (Suzhou, China) Recent Developments Table 28. Qilu Pharmaceutical Company Information Table 29. Qilu Pharmaceutical Business Overview Table 30. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 32. Qilu Pharmaceutical Recent Developments Table 33. Nanjing Healthnice Pharmaceutical Company Information Table 34. Nanjing Healthnice Pharmaceutical Business Overview Table 35. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 37. Nanjing Healthnice Pharmaceutical Recent Developments Table 38. HEC Pharm Company Information Table 39. HEC Pharm Business Overview Table 40. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio Table 42. HEC Pharm Recent Developments Table 43. Cisen Pharmaceutical Company Information Table 44. Cisen Pharmaceutical Business Overview Table 45. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 47. Cisen Pharmaceutical Recent Developments Table 48. Zydus Company Information Table 49. Zydus Business Overview Table 50. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Zydus Oral Medications for Multiple Sclerosis Product Portfolio Table 52. Zydus Recent Developments Table 53. Viatris Company Information Table 54. Viatris Business Overview Table 55. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Viatris Oral Medications for Multiple Sclerosis Product Portfolio Table 57. Viatris Recent Developments Table 58. Teva Company Information Table 59. Teva Business Overview Table 60. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Teva Oral Medications for Multiple Sclerosis Product Portfolio Table 62. Teva Recent Developments Table 63. Sun Pharmaceuticals Company Information Table 64. Sun Pharmaceuticals Business Overview Table 65. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 67. Sun Pharmaceuticals Recent Developments Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sanofi Oral Medications for Multiple Sclerosis Product Portfolio Table 72. Sanofi Recent Developments Table 73. Sandoz Company Information Table 74. Sandoz Business Overview Table 75. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sandoz Oral Medications for Multiple Sclerosis Product Portfolio Table 77. Sandoz Recent Developments Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Novartis Oral Medications for Multiple Sclerosis Product Portfolio Table 82. Novartis Recent Developments Table 83. Mylan Company Information Table 84. Mylan Business Overview Table 85. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Mylan Oral Medications for Multiple Sclerosis Product Portfolio Table 87. Mylan Recent Developments Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Merck Oral Medications for Multiple Sclerosis Product Portfolio Table 92. Merck Recent Developments Table 93. Janssen Company Information Table 94. Janssen Business Overview Table 95. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Janssen Oral Medications for Multiple Sclerosis Product Portfolio Table 97. Janssen Recent Developments Table 98. Glenmark Pharmaceuticals Company Information Table 99. Glenmark Pharmaceuticals Business Overview Table 100. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 102. Glenmark Pharmaceuticals Recent Developments Table 103. Dr. Reddy's Laboratories Company Information Table 104. Dr. Reddy's Laboratories Business Overview Table 105. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio Table 107. Dr. Reddy's Laboratories Recent Developments Table 108. Bristol Myers Squibb Company Information Table 109. Bristol Myers Squibb Business Overview Table 110. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio Table 112. Bristol Myers Squibb Recent Developments Table 113. Biogen Company Information Table 114. Biogen Business Overview Table 115. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Biogen Oral Medications for Multiple Sclerosis Product Portfolio Table 117. Biogen Recent Developments Table 118. Banner Life Sciences Company Information Table 119. Banner Life Sciences Business Overview Table 120. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio Table 122. Banner Life Sciences Recent Developments Table 123. Apotex Company Information Table 124. Apotex Business Overview Table 125. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Apotex Oral Medications for Multiple Sclerosis Product Portfolio Table 127. Apotex Recent Developments Table 128. Alembic Company Information Table 129. Alembic Business Overview Table 130. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Alembic Oral Medications for Multiple Sclerosis Product Portfolio Table 132. Alembic Recent Developments Table 133. Accord Healthcare Company Information Table 134. Accord Healthcare Business Overview Table 135. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio Table 137. Accord Healthcare Recent Developments Table 138. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 139. Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026) & (K Units) Table 140. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2021-2026) Table 141. Global Oral Medications for Multiple Sclerosis Sales by Region (2027-2032) & (K Units) Table 142. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2027-2032) Table 143. Global Oral Medications for Multiple Sclerosis Revenue by Region (2021-2026) & (US$ Million) Table 144. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2021-2026) Table 145. Global Oral Medications for Multiple Sclerosis Revenue by Region (2027-2032) & (US$ Million) Table 146. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2027-2032) Table 147. North America Oral Medications for Multiple Sclerosis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. North America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 149. North America Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 150. North America Oral Medications for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Oral Medications for Multiple Sclerosis Revenue by Country (2027-2032) & (US$ Million) Table 152. Europe Oral Medications for Multiple Sclerosis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Europe Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 154. Europe Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 155. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 156. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2027-2032) & (US$ Million) Table 157. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 159. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 160. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 161. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Country (2027-2032) & (US$ Million) Table 162. South America Oral Medications for Multiple Sclerosis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. South America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 164. South America Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 165. South America Oral Medications for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 166. South America Oral Medications for Multiple Sclerosis Revenue by Country (2027-2032) & (US$ Million) Table 167. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 169. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 170. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 171. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2027-2032) & (US$ Million) Table 172. Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 173. Global Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 174. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2026) Table 175. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2027-2032) Table 176. Global Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 177. Global Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 178. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2026) Table 179. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2027-2032) Table 180. Global Oral Medications for Multiple Sclerosis Price by Type (2021-2026) & (US$/Unit) Table 181. Global Oral Medications for Multiple Sclerosis Price by Type (2027-2032) & (US$/Unit) Table 182. Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 183. Global Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 184. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2026) Table 185. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2027-2032) Table 186. Global Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 187. Global Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 188. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2026) Table 189. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2027-2032) Table 190. Global Oral Medications for Multiple Sclerosis Price by Application (2021-2026) & (US$/Unit) Table 191. Global Oral Medications for Multiple Sclerosis Price by Application (2027-2032) & (US$/Unit) Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Oral Medications for Multiple Sclerosis Distributors List Table 195. Oral Medications for Multiple Sclerosis Customers List Table 196. Oral Medications for Multiple Sclerosis Industry Trends Table 197. Oral Medications for Multiple Sclerosis Industry Drivers Table 198. Oral Medications for Multiple Sclerosis Industry Restraints Table 199. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oral Medications for Multiple Sclerosis Product Image Figure 5. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oral Medications for Multiple Sclerosis Market Size (2021-2032) & (US$ Million) Figure 7. Global Oral Medications for Multiple Sclerosis Sales (2021-2032) & (K Units) Figure 8. Global Oral Medications for Multiple Sclerosis Average Price (US$/Unit) & (2021-2032) Figure 9. Ozanimod Product Image Figure 10. Ponesimod Product Image Figure 11. Fingolimod Product Image Figure 12. Diroximel Fumarate Product Image Figure 13. Monomethyl Fumarate Product Image Figure 14. Dimethyl Fumarate Product Image Figure 15. Cladribine Product Image Figure 16. Teriflunomide Product Image Figure 17. Siponimod Product Image Figure 18. Hospital and Clinic Product Image Figure 19. Retail Pharmacies Product Image Figure 20. Other Product Image Figure 21. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers in 2025 Figure 22. Global Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters Figure 23. Global Top 5 and 10 Oral Medications for Multiple Sclerosis Players Market Share by Revenue in 2025 Figure 24. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 26. Global Oral Medications for Multiple Sclerosis Sales by Region in 2025 Figure 27. Global Oral Medications for Multiple Sclerosis Revenue by Region in 2025 Figure 28. North America Oral Medications for Multiple Sclerosis Market Size by Country in 2025 Figure 29. North America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 30. North America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2021-2032) Figure 31. United States Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Canada Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Mexico Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Europe Oral Medications for Multiple Sclerosis Market Size by Country in 2025 Figure 35. Europe Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 36. Europe Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2021-2032) Figure 37. Germany Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. France Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. U.K. Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Italy Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Russia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Spain Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Netherlands Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Switzerland Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Sweden Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Poland Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Asia Pacific Oral Medications for Multiple Sclerosis Market Size by Country in 2025 Figure 48. Asia Pacific Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 49. Asia Pacific Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2021-2032) Figure 50. China Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Japan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South Korea Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. India Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Australia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Taiwan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Southeast Asia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Southeast Asia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. South America Oral Medications for Multiple Sclerosis Market Size by Country in 2025 Figure 59. South America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 60. South America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2021-2032) Figure 61. Brazil Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Argentina Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Chile Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country in 2025 Figure 65. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 66. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2021-2032) Figure 67. Egypt Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. South Africa Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Israel Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Türkiye Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. GCC Countries Oral Medications for Multiple Sclerosis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 72. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2032) Figure 73. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2032) Figure 74. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2021-2032) Figure 75. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2032) Figure 76. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2032) Figure 77. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2021-2032) Figure 78. Oral Medications for Multiple Sclerosis Value Chain Figure 79. Oral Medications for Multiple Sclerosis Production Mode & Process Figure 80. Direct Comparison with Distribution Share Figure 81. Distributors Profiles Figure 82. Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges

Scope & coverage.

Types
  • Ozanimod
  • Ponesimod
  • Fingolimod
  • Diroximel Fumarate
  • Monomethyl Fumarate
  • Dimethyl Fumarate
  • Cladribine
  • Teriflunomide
  • Siponimod
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Sichuan Omnis Pharmaceutical
  • CGeneTech (Suzhou, China)
  • Qilu Pharmaceutical
  • Nanjing Healthnice Pharmaceutical
  • HEC Pharm
  • Cisen Pharmaceutical
  • Zydus
  • Viatris
  • Teva
  • Sun Pharmaceuticals
  • Sanofi
  • Sandoz
  • Novartis
  • Mylan
  • Merck
  • Janssen
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Bristol Myers Squibb
  • Biogen
  • Banner Life Sciences
  • Apotex
  • Alembic
  • Accord Healthcare

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oral Medications for Multiple Sclerosis Market Size (2021-2032)
  4. 2.2.2 Global Oral Medications for Multiple Sclerosis Sales (2021-2032)
  5. 2.2.3 Global Oral Medications for Multiple Sclerosis Market Average Price (2021-2032)
  6. 2.3 Oral Medications for Multiple Sclerosis by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Ozanimod
  9. 2.3.3 Ponesimod
  10. 2.3.4 Fingolimod
  11. 2.3.5 Diroximel Fumarate
  12. 2.3.6 Monomethyl Fumarate
  13. 2.3.7 Dimethyl Fumarate
  14. 2.3.8 Cladribine
  15. 2.3.9 Teriflunomide
  16. 2.3.10 Siponimod
  17. 2.4 Oral Medications for Multiple Sclerosis by Application
  18. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  19. 2.4.2 Hospital and Clinic
  20. 2.4.3 Retail Pharmacies
  21. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oral Medications for Multiple Sclerosis Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oral Medications for Multiple Sclerosis Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Oral Medications for Multiple Sclerosis Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oral Medications for Multiple Sclerosis Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oral Medications for Multiple Sclerosis Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oral Medications for Multiple Sclerosis, Product Type & Application
  8. 3.8 Global Manufacturers of Oral Medications for Multiple Sclerosis, Established Date
  9. 3.9 Global Oral Medications for Multiple Sclerosis Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sichuan Omnis Pharmaceutical
  2. 4.1.1 Sichuan Omnis Pharmaceutical Company Information
  3. 4.1.2 Sichuan Omnis Pharmaceutical Business Overview
  4. 4.1.3 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  6. 4.1.5 Sichuan Omnis Pharmaceutical Recent Developments
  7. 4.2 CGeneTech (Suzhou, China)
  8. 4.2.1 CGeneTech (Suzhou, China) Company Information
  9. 4.2.2 CGeneTech (Suzhou, China) Business Overview
  10. 4.2.3 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio
  12. 4.2.5 CGeneTech (Suzhou, China) Recent Developments
  13. 4.3 Qilu Pharmaceutical
  14. 4.3.1 Qilu Pharmaceutical Company Information
  15. 4.3.2 Qilu Pharmaceutical Business Overview
  16. 4.3.3 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  18. 4.3.5 Qilu Pharmaceutical Recent Developments
  19. 4.4 Nanjing Healthnice Pharmaceutical
  20. 4.4.1 Nanjing Healthnice Pharmaceutical Company Information
  21. 4.4.2 Nanjing Healthnice Pharmaceutical Business Overview
  22. 4.4.3 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  24. 4.4.5 Nanjing Healthnice Pharmaceutical Recent Developments
  25. 4.5 HEC Pharm
  26. 4.5.1 HEC Pharm Company Information
  27. 4.5.2 HEC Pharm Business Overview
  28. 4.5.3 HEC Pharm Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio
  30. 4.5.5 HEC Pharm Recent Developments
  31. 4.6 Cisen Pharmaceutical
  32. 4.6.1 Cisen Pharmaceutical Company Information
  33. 4.6.2 Cisen Pharmaceutical Business Overview
  34. 4.6.3 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  36. 4.6.5 Cisen Pharmaceutical Recent Developments
  37. 4.7 Zydus
  38. 4.7.1 Zydus Company Information
  39. 4.7.2 Zydus Business Overview
  40. 4.7.3 Zydus Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Zydus Oral Medications for Multiple Sclerosis Product Portfolio
  42. 4.7.5 Zydus Recent Developments
  43. 4.8 Viatris
  44. 4.8.1 Viatris Company Information
  45. 4.8.2 Viatris Business Overview
  46. 4.8.3 Viatris Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Viatris Oral Medications for Multiple Sclerosis Product Portfolio
  48. 4.8.5 Viatris Recent Developments
  49. 4.9 Teva
  50. 4.9.1 Teva Company Information
  51. 4.9.2 Teva Business Overview
  52. 4.9.3 Teva Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Teva Oral Medications for Multiple Sclerosis Product Portfolio
  54. 4.9.5 Teva Recent Developments
  55. 4.10 Sun Pharmaceuticals
  56. 4.10.1 Sun Pharmaceuticals Company Information
  57. 4.10.2 Sun Pharmaceuticals Business Overview
  58. 4.10.3 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  60. 4.10.5 Sun Pharmaceuticals Recent Developments
  61. 4.11 Sanofi
  62. 4.11.1 Sanofi Company Information
  63. 4.11.2 Sanofi Business Overview
  64. 4.11.3 Sanofi Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sanofi Oral Medications for Multiple Sclerosis Product Portfolio
  66. 4.11.5 Sanofi Recent Developments
  67. 4.12 Sandoz
  68. 4.12.1 Sandoz Company Information
  69. 4.12.2 Sandoz Business Overview
  70. 4.12.3 Sandoz Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Sandoz Oral Medications for Multiple Sclerosis Product Portfolio
  72. 4.12.5 Sandoz Recent Developments
  73. 4.13 Novartis
  74. 4.13.1 Novartis Company Information
  75. 4.13.2 Novartis Business Overview
  76. 4.13.3 Novartis Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Novartis Oral Medications for Multiple Sclerosis Product Portfolio
  78. 4.13.5 Novartis Recent Developments
  79. 4.14 Mylan
  80. 4.14.1 Mylan Company Information
  81. 4.14.2 Mylan Business Overview
  82. 4.14.3 Mylan Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Mylan Oral Medications for Multiple Sclerosis Product Portfolio
  84. 4.14.5 Mylan Recent Developments
  85. 4.15 Merck
  86. 4.15.1 Merck Company Information
  87. 4.15.2 Merck Business Overview
  88. 4.15.3 Merck Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Merck Oral Medications for Multiple Sclerosis Product Portfolio
  90. 4.15.5 Merck Recent Developments
  91. 4.16 Janssen
  92. 4.16.1 Janssen Company Information
  93. 4.16.2 Janssen Business Overview
  94. 4.16.3 Janssen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Janssen Oral Medications for Multiple Sclerosis Product Portfolio
  96. 4.16.5 Janssen Recent Developments
  97. 4.17 Glenmark Pharmaceuticals
  98. 4.17.1 Glenmark Pharmaceuticals Company Information
  99. 4.17.2 Glenmark Pharmaceuticals Business Overview
  100. 4.17.3 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  102. 4.17.5 Glenmark Pharmaceuticals Recent Developments
  103. 4.18 Dr. Reddy's Laboratories
  104. 4.18.1 Dr. Reddy's Laboratories Company Information
  105. 4.18.2 Dr. Reddy's Laboratories Business Overview
  106. 4.18.3 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio
  108. 4.18.5 Dr. Reddy's Laboratories Recent Developments
  109. 4.19 Bristol Myers Squibb
  110. 4.19.1 Bristol Myers Squibb Company Information
  111. 4.19.2 Bristol Myers Squibb Business Overview
  112. 4.19.3 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio
  114. 4.19.5 Bristol Myers Squibb Recent Developments
  115. 4.20 Biogen
  116. 4.20.1 Biogen Company Information
  117. 4.20.2 Biogen Business Overview
  118. 4.20.3 Biogen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Biogen Oral Medications for Multiple Sclerosis Product Portfolio
  120. 4.20.5 Biogen Recent Developments
  121. 4.21 Banner Life Sciences
  122. 4.21.1 Banner Life Sciences Company Information
  123. 4.21.2 Banner Life Sciences Business Overview
  124. 4.21.3 Banner Life Sciences Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio
  126. 4.21.5 Banner Life Sciences Recent Developments
  127. 4.22 Apotex
  128. 4.22.1 Apotex Company Information
  129. 4.22.2 Apotex Business Overview
  130. 4.22.3 Apotex Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Apotex Oral Medications for Multiple Sclerosis Product Portfolio
  132. 4.22.5 Apotex Recent Developments
  133. 4.23 Alembic
  134. 4.23.1 Alembic Company Information
  135. 4.23.2 Alembic Business Overview
  136. 4.23.3 Alembic Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Alembic Oral Medications for Multiple Sclerosis Product Portfolio
  138. 4.23.5 Alembic Recent Developments
  139. 4.24 Accord Healthcare
  140. 4.24.1 Accord Healthcare Company Information
  141. 4.24.2 Accord Healthcare Business Overview
  142. 4.24.3 Accord Healthcare Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio
  144. 4.24.5 Accord Healthcare Recent Developments
5 Global Oral Medications for Multiple Sclerosis Market Scenario by Region
  1. 5.1 Global Oral Medications for Multiple Sclerosis Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oral Medications for Multiple Sclerosis Sales by Region: 2021-2032
  3. 5.2.1 Global Oral Medications for Multiple Sclerosis Sales by Region: 2021-2026
  4. 5.2.2 Global Oral Medications for Multiple Sclerosis Sales by Region: 2027-2032
  5. 5.3 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2021-2032
  6. 5.3.1 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2021-2026
  7. 5.3.2 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2027-2032
  8. 5.4 North America Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
  9. 5.4.1 North America Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  11. 5.4.3 North America Oral Medications for Multiple Sclerosis Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
  16. 5.5.1 Europe Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  18. 5.5.3 Europe Oral Medications for Multiple Sclerosis Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
  41. 5.7.1 South America Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  43. 5.7.3 South America Oral Medications for Multiple Sclerosis Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2032)
  2. 6.1.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032)
  5. 6.2.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oral Medications for Multiple Sclerosis Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2032)
  2. 7.1.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032)
  5. 7.2.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oral Medications for Multiple Sclerosis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oral Medications for Multiple Sclerosis Value Chain Analysis
  2. 8.1.1 Oral Medications for Multiple Sclerosis Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oral Medications for Multiple Sclerosis Production Mode & Process
  5. 8.2 Oral Medications for Multiple Sclerosis Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oral Medications for Multiple Sclerosis Distributors
  8. 8.2.3 Oral Medications for Multiple Sclerosis Customers
9 Global Oral Medications for Multiple Sclerosis Analyzing Market Dynamics
  1. 9.1 Oral Medications for Multiple Sclerosis Industry Trends
  2. 9.2 Oral Medications for Multiple Sclerosis Industry Drivers
  3. 9.3 Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges
  4. 9.4 Oral Medications for Multiple Sclerosis Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst